within Pharmacolibrary.Drugs.ATC.L;

model L01BC53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.42,
    Cl             = 11.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,
    adminCount     = 1,
    Vd             = 0.048,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tegafur, in combinations (ATC L01BC53), is an oral chemotherapeutic agent used mainly in conjunction with other agents such as uracil or gimeracil and oteracil (as S-1 formulation) for the treatment of various solid tumors, especially gastric and colorectal cancer. It is a prodrug of 5-fluorouracil (5-FU) that is bioactivated in the body, and these combinations are approved and still in clinical use for several cancer indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (mixed sex, typical age range 40-70 years) receiving S-1 (tegafur/gimeracil/oteracil) orally.</p><h4>References</h4><ol><li><p>Wellington, K, &amp; Goa, KL (2001). Oral tegafur/uracil. <i>Drugs &amp; aging</i> 18(12) 935–950. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200118120-00005&quot;>10.2165/00002512-200118120-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11888348/&quot;>https://pubmed.ncbi.nlm.nih.gov/11888348</a></p></li><li><p>Kobuchi, S, et al., &amp; Sakaeda, T (2018). Circadian variations in the pharmacokinetics of the oral anticancer agent tegafur-uracil (UFT) and its metabolites in rats. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 123 452–458. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2018.08.004&quot;>10.1016/j.ejps.2018.08.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30077713/&quot;>https://pubmed.ncbi.nlm.nih.gov/30077713</a></p></li><li><p>Hirata, K, et al., &amp; Shirasaka, T (2006). [Pharmacokinetics of S-1]. <i>Gan to kagaku ryoho. Cancer &amp; chemotherapy</i> 33 Suppl 1 27–35. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16897969/&quot;>https://pubmed.ncbi.nlm.nih.gov/16897969</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC53;
